GLP‑1s shift fitness talk

GLP-1 drugs that cut appetite and body weight are now pushing a second question into gyms and clinics: how to keep strength while the scale drops. (nejm.org) (onlinelibrary.wiley.com) Semaglutide, sold as Wegovy, produced average weight loss of 14.9% at 68 weeks in a 1,961-person trial published in 2021. Tirzepatide, sold as Zepbound, produced 15.0% to 20.9% average weight loss at 72 weeks in a 2,539-person trial published in 2022. (nejm.org 1) (nejm.org 2) When people lose that much weight, they do not lose fat alone. In a DXA scan subgroup from the semaglutide trial, total lean body mass fell in absolute terms even as the proportion of lean mass increased; in tirzepatide body-composition data, fat mass fell by about three times as much as lean mass. (nejm.org 1) (nejm.org 2) Lean mass is not the same thing as muscle, because it also includes water, organs and other tissue. A 2024 review in *Diabetes, Obesity and Metabolism* said reported lean-mass reductions in GLP-1 studies ranged from about 15% to 60% of total weight lost, with wide differences by drug, population and measurement method. (onlinelibrary.wiley.com) (ahajournals.org) That is why the fitness conversation has shifted from “How much weight did you lose?” to “What happened to your strength, protein intake and training volume?” A 2025 *Nature Reviews Endocrinology* comment said rapid weight loss with GLP-1 receptor agonists can come at the cost of skeletal muscle and argued for treatment plans that prioritize muscle preservation. (nature.com) The drugs’ labels already frame them as part of a broader routine, not a stand-alone fix. Wegovy and Zepbound are indicated with a reduced-calorie diet and increased physical activity, and both carry boxed warnings about thyroid C-cell tumors seen in rodents; both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (novo-pi.com) (pi.lilly.com) Sports-medicine guidance has moved in the same direction. In March 2026, the American College of Sports Medicine said adults should train all major muscle groups at least twice a week, and its updated guidance said consistency matters more than a complicated plan. (acsm.org) Researchers are still arguing over how much of the muscle change is harmful and how much is a normal adjustment to carrying less body weight. A 2024 *Circulation* primer said the key question is whether changes in muscle with GLP-1 treatment are maladaptive, adaptive or even part of improved muscle health after weight loss. (ahajournals.org) (jamanetwork.com) For people using these drugs, the practical advice emerging from trials, reviews and exercise guidance is narrower than the hype: watch food intake, keep lifting, and judge progress by function as well as pounds. (onlinelibrary.wiley.com) (acsm.org)